SkinBio announces closure of its convertible bond facility

(Alliance News) - SkinBioTherapeutics PLC announced on Tuesday the closure of its convertible ...

Alliance News 23 July, 2024 | 1:59PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - SkinBioTherapeutics PLC announced on Tuesday the closure of its convertible bond facility.

The skin health-focused life science company received the final conversion notice from Macquarie for GBP480,000 on Monday of convertible bonds from the initial GBP5.0 million convertible bond facility announced earlier in the year.

SkinBio has drawn a total of GBP1.6 million under the facility. It had announced it would not draw any further funds from the facility back in February.

The Newcastle, England-based firm will issue 5.8 million new ordinary shares at a conversion price of 8.21p per share, likely on Friday.

Chief Executive Officer Stuart Ashman said: "We are pleased that the [convertible loan note] has now come to an end. Having listened to shareholder sentiment, we made the decision not to use the remainder of the facility. We have worked to reduce the initial loan note as swiftly as possible. Whilst the term of the note was designed to span two years, the entire facility has now been converted within six months of its introduction".

SkinBio shares were up 21% at 11.05p per share in London on Tuesday afternoon.

By Lydia Doye, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
SkinBioTherapeutics PLC 12.40 GBX 5.53 -
Macquarie Group Ltd 204.67 AUD 1.52

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures